May 27 2022




Recommendations

Risks to the infant

Have been some cases of abdominal colic, sleep disturbance, vomiting, loose stools and more rarely hyperactivity or irritability in neonates and infants whose mothers received fluoxetine. The Australian Pharmacovigilance system records the increase in blood glucose in an infant exposed during five months at fluoxetine through milk.

It has been observed a decrease in weight in infants of mothers who received fluoxetine, but without exceeding the normal range. This data would require confirmation. The follow-up of infants exposed to fluoxetine seems to detect differences in development regarding unexposed children. In some children was detected a slight delay in psychomotor development, although it can not determine the possible influence of the drug, given the concurrence of other factors.

Platelet serotonin record (PS) in infants and mothers showed no influence of the fluoxetine on PS of children.

Influence on lactation

Fluoxetine passes into breast milk in higher degree that other antidepressants and can be detected in most of infants during the first trimester of life.

Published studies indicate varying values ??for the amount of fluoxetine that ingests an infant whose mother received a standard dose of the drug, typically varying between 2.4% and 3.8% of the weight adjusted dose and 7% including norfluoxetine, the major active metabolite.

Fluoxetine in infants can reach a figure of 7% maternal rate, although in some cases there has been up to 10% or greater. In infants whose mothers took the drug during pregnancy can be achieved blood concentrations three or four times higher, which are interpreted as transplacental origin.

Fluoxetine, like other drugs, can cause elevated blood prolactin and galactorrhea. The clinical significance of this effect on lactation is unknown, although probably not directly affects to breastfeeding.

Recommendations

The effect on infants whose mothers received fluoxetine is unknown, but may be of concern and should be monitored closely for symptoms of fluoxetine impact on children.

References:

1.Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations.Clin Pharmacokinet. 1988 Apr;14(4):217-40.
2.Arya DK, Taylor WS. Lactation associated with fluoxetine treatment. Aust N Z J Psychiatry. 1995;29:697.
3. Berle JO, Steen VM, Aamo TO et al. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. J Clin Psychiatry. 2004;65:1228-34.
4.Brent NB, Wisner KL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin Pediatr. 1998;37:41-4.
5.Burch KJ, Wells BG. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics. 1992 Apr;89(4 Pt 1):676-7.
6.Casper RC, Fleisher BE, Lee-Ancajas JC et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142:402-8.
7.Chambers CD, Anderson PO, Thomas RG et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics. 1999;104:e61.
8.Egberts ACG, Meyboom RHB, De Koning FHP et al. Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol. 1997;44:277-81.
9.Epperson CN, Jatlow PI, Czarkowski K, Anderson GM. Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs. Pediatrics. 2003 Nov;112(5):e425.
10.Hale TW, Shum S, Grossberg M. Fluoxetine toxicity in a breastfed infant. Clin Pediatr. 2001;40:681-4.
11.Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation.Clin Pharmacol Ther. 2003 Apr;73(4):330-7.
12. Hendrick V, Smith LM, Hwang S et al. Weight gain in breastfed infants of mothers taking antidepressant medications. J Clin Psychiatry. 2003;64:410-2.
13.Hendrick V, Stowe ZN, Altshuler LL, Mintz J, Hwang S, Hostetter A, Suri R, Leight K, Fukuchi A. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psychiatry. 2001 Nov 15;50(10):775-82.
14. Isenberg KE. Excretion of fluoxetine in human breast milk. J Clin Psychiatry. 1990;51:169.
15.Kim J, Riggs KW, Misri S, Kent N, Oberlander TF, Grunau RE, Fitzgerald C, Rurak DW. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol. 2006 Feb;61(2):155-63.
16.Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol. 1999 Oct;48(4):521-7.
17.Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry. 1993 Nov;32(6):1253-5.
18: Llewellyn A, Stowe ZN. Psychotropic medications in lactation. J Clin Psychiatry. 1998;59 Suppl 2:41-52.
19. Moretti ME, Sharma A, Bar-Oz B et al. Fluoxetine and its effects on the nursing infant: a prospective cohort. Clin Pharmacol Ther. 1999;65:141.
20.[Ningún autor referido] Can a woman breastfeed while taking Prozac? J Hum Lact. 1991 Sep;7(3):144.
21.Nulman I, Rovet J, Stewart DE et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159:1889-953.
22. Rohan A. Drug distribution in human milk. Aust Prescriber. 1997;20:84.
23.Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics. 1993 Nov;92(5):721-2.
24.Suri R, Stowe ZN, Hendrick V, Hostetter A, Widawski M, Altshuler LL. Estimates of nursing infant daily dose of fluoxetine through breast milk. Biol Psychiatry. 2002 Sep 1;52(5):446-51.
25.Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol. 1996 Jan;36(1):42-7.
26.Weissman AM, Levy BT, Hartz AJ, Bentler S, Donohue M, Ellingrod VL, Wisner KL. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants.Am J Psychiatry. 2004 Jun;161(6):1066-78.
27.Yoshida K, Smith B, Craggs M, Kumar RC. Fluoxetine in breast-milk and developmental outcome of breast-fed infants. Br J Psychiatry. 1998 Feb;172:175-8. 28.Yoshida K, Smith B, Craggs M, Kumar R. Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants. Psychol Med. 1998 Jan;28(1):81-91.

Warning of the manufacturer:

Updated:23.03.08